Khan Khalid, Schwarzenberg Sara Jane, Sharp Harvey L, Matas Arthur J, Chavers Blanche M
Division of Pediatric Gastroenterology and Nutrition, University of Minnesota, Minneapolis 55455, USA.
Am J Transplant. 2002 Apr;2(4):360-5. doi: 10.1034/j.1600-6143.2002.20412.x.
Presentation of autosomal recessive polycystic kidney disease (ARPKD) ranges from severe renal impairment and a high mortality rate in infancy to older children and adolescents with minimal renal disease and complications of congenital hepatic fibrosis (CHF), cholangitis and portal hypertension. Renal transplantation improves prognosis but it is unclear whether CHF in transplanted children follows the same clinical course as in older children with less severe renal disease. The aim of this study was to evaluate morbidity from CHF in ARPKD post renal transplantation. Data were analyzed for six males and eight females, transplanted for ARPKD (mean age 8.3 years, range 1-22.3 years) at the University of Minnesota between 1972 and 1998. Follow-up was for a mean of 14.5 years (range 3.1-33.6 years). One and 5 years patient survival rates were 93% and 86%, respectively. Overall five patients (36%) died; 4/5 deaths were related to CHF. Causes of death were hepatic failure immediately post transplant (n = 1), septicemia related to bile duct dilatation (n = 3) and multiorgan failure (n = 1). One and 5years graft survival rates were 87% and 70%, respectively. One patient had a combined liver-kidney transplant and two were re-transplanted. Initial signs of CHF were splenomegaly (n = 5), hepatosplenomegaly (n = 4) and gastrointestinal bleed (n = 2). Progression of CHF through childhood included hypersplenism (n = 7), esophageal varices with gastrointestinal bleeding (n = 5) and bile duct dilatation (n = 5). Portal hypertension was treated with portosystemic shunt (n = 3), sclerotherapy (n = 2), banding of varices (n = 1) and transjugular intrahepatic portosystemic shunt (n = 1). Of the nine survivors (mean age 12.8 years) 78% have functioning grafts (one liver-kidney transplant), 63% have portal hypertension and 22% have asymptomatic biliary dilatation. Complications of CHF developed in 79% of children who received a renal transplant for ARPKD. Mortality related to CHF occurred in 29% and accounted for 80% (4/5) of the deaths.
常染色体隐性多囊肾病(ARPKD)的临床表现范围广泛,从婴儿期严重的肾功能损害和高死亡率到患有轻度肾病以及先天性肝纤维化(CHF)、胆管炎和门静脉高压并发症的大龄儿童及青少年。肾移植可改善预后,但尚不清楚接受移植的儿童中的CHF是否与肾病较轻的大龄儿童具有相同的临床病程。本研究的目的是评估ARPKD肾移植后CHF的发病率。分析了1972年至1998年间在明尼苏达大学因ARPKD接受移植的6名男性和8名女性的数据(平均年龄8.3岁,范围1 - 22.3岁)。随访平均时间为14.5年(范围3.1 - 33.6年)。1年和5年的患者生存率分别为93%和86%。总体有5名患者(36%)死亡;5例死亡中有4例与CHF相关。死亡原因分别为移植后立即出现的肝衰竭(n = 1)、与胆管扩张相关的败血症(n = 3)和多器官衰竭(n = 1)。1年和5年的移植物生存率分别为87%和70%。1例患者接受了肝肾联合移植,2例接受了再次移植。CHF的初始体征为脾肿大(n = 5)、肝脾肿大(n = 4)和胃肠道出血(n = 2)。CHF在儿童期的进展包括脾功能亢进(n = 7)、伴有胃肠道出血的食管静脉曲张(n = 5)和胆管扩张(n = 5)。门静脉高压采用门体分流术(n = 3)、硬化疗法(n = 2)、静脉曲张套扎术(n = 1)和经颈静脉肝内门体分流术(n = 1)进行治疗。在9名幸存者(平均年龄12.8岁)中,78%的患者移植物功能良好(1例为肝肾联合移植),63%的患者患有门静脉高压,22%的患者有无症状胆管扩张。接受ARPKD肾移植的儿童中,79%出现了CHF并发症。与CHF相关的死亡率为29%,占死亡人数的80%(4/5)。